Barrett AM, Eslinger PJ: Amantadine for adynamic speech: possible benefit for aphasia? Am J Phys Med Rehabil 2007;86:605-612. Objective: Dopaminergic agents may stimulate behavior and verbal expression after frontal lobe dysfunction. Although amantadine is used in neurorehabilitation of motivational disorders and head injury, it is not commonly prescribed to improve aphasia. This pilot study examined verbal fluency on and off amantadine for nonfluent speech.
cognitive neuropsychological models could be considered true translational rehabilitation. Physiologic treatment might be defined as somatic interventions to induce bodily changes directly, as contrasted with behavioral treatment, which consists of controlling learning experiences to induce neurophysiological change indirectly. Unfortunately, a process of scientific translational method is still developing for physiologic rehabilitation in the acquired speech and language disorder, aphasia.
Nonfluent aphasia occurs with poststroke brain injury when subjects have (1) abnormal spontaneous speech and communication ability, with a conversation partner making the major portion of the effort supporting verbal commu-nication, and (2) nonfluent speech (fewer than 50 words per minute generated in response to an open-ended question such as "How did you come to the hospital?"). Even when subjects have relatively spared comprehension ability, the disability associated with nonfluent aphasia is considerable. Selfinitiated verbal messages are a part of almost all daily life settings, and an impairment of spontaneous speech in nonfluent aphasia can significantly limit independence and psychosocial function. 1 Other disorders primarily affecting attention (the ability to focus, remain vigilant, and ignore irrelevant stimuli) or conation (amotivational or apathetic states) may also produce a combination of communication disorder and nonfluent speech. We would suggest that although their problem is of a different origin, these patients are also significantly disabled.
Ideally, pharmacotherapy of aphasia might begin with an agent selected because its predicted mechanisms of action correspond with specific dysfunctional processing in brain-behavior systems, or because an agent is known to act on neurotransmitter-neuroanatomic networks critical to a dysfunctional processes. However, the theoretical basis for improvement with some currently proposed agents for pharmacotherapy of aphasia is not specific to dysfunctional cognitive mechanisms. Instead, agents are often used that may benefit brain function more generally (e.g., decrease poststroke diaschisis, induce a permissive state for plastic remodeling, or improve brain metabolic activity). 2 Both stimulants and dopamine agonists (e.g., bromocriptine) may stimulate behavior in braininjured patients with frontal lobe syndromes (for a review, see DeMarchi et al. 3 ). Dopamine agonists may also be helpful for aphasia. 4 Amantadine, which has prodopaminergic and anticholinergic effects, has been in use for many years, has few side effects, and is safe 5,6 and inexpensive. 7 Its primary indications in medicine, neurology, and rehabilitation include use as an antiviral, 7 for fatigue accompanying chronic neurological disorders, 8 and to improve hyperkinetic and parkinsonian movement disorders. 9 It is also widely used in neurologic rehabilitation for motivational disorders/minimally conscious state after traumatic brain injury (TBI). 10,11,11a In contrast, it is not common rehabilitative practice to prescribe amantadine for communication disorders or nonfluent aphasia. In many rehabilitative settings, in fact, standard care of communication disorders in acute or chronic stages does not combine pharmacologic and behavioral treatment.
The magnitude of the problem of acute and chronic poststroke aphasia mandates wider action to improve its disability. 12 There are an estimated one million stroke survivors with aphasia in the United States alone 13 ; thus, a low-risk agent with even minor likelihood to benefit communication might have a significant impact on decreasing the individual and national burden of communication disorder, in lost work time for people with aphasia and their caregivers, dollars spent on care, and reduced quality of life.
Specific information about a possible effect of amantadine on nonfluent aphasia is not easily obtained. To locate recent studies on the use of amantadine in aphasia rehabilitation, we performed a Medline search of published literature (1966 to present) and a Psychlit search of literature (1872 to present) using the terms aphasia, rehabilitation, and amantadine, which identified no articles on either database. Searching aphasia and amantadine identified via Medline one Japanese language article on improvement of perseverative speech in three patients with 200 mg of amantadine daily. 14 We then combined the search terms amantadine and verbal behavior to search both databases, but, again, no therapeutic articles were identified. Medline identified a case report of amantadine-induced vocal myoclonus. 15 We examined selected existing studies on the effects of amantadine on attention and cognitive function, to determine whether improvement in verbal fluency in patients meeting diagnostic criteria for aphasia was reported. Schneider et al. 16 report that 300 mg/day of amantadine administered orally to traumatic brain-injured patients, given in a placebo-controlled fashion to assess improvement in attention and higher cognitive skills, and reduction of agitation, did not have significant effects. Naming and verbal fluency were examined in this negative study, but these two measures were collapsed into a composite cognitive variable, and so medication effect is difficult to determine. In a case study reporting benefits of amantadine treatment in a patient with posthypoxic encephalopathy and transcortical sensory aphasia, Arciniegas et al. 17 include a summary statement that verbal fluency improved on amantadine, declined when it was tapered, and improved again when amantadine was reinstated. However, the patient's fluency and how it was evaluated were not specified. We were, thus, unable to find specific reporting of improved language output or verbal fluency with accompanying documentation.
One of us (A.M.B.) previously attended on an acute inpatient neurological rehabilitation service. Established standard evaluation of patients with brain injury by the resident physician staff included assessing frontal lobe function and testing speech and language, including verbal fluency. A standard treatment administered to patients identified on screening as having frontal lobe dysfunction of the amotivational type, including isolated nonfluent speech, was 100 mg of amantadine administered orally twice daily. To address the lack of specific reports of amantadine benefit in nonfluent aphasia, we retrospectively examined data collected on patients admitted for inpatient neurorehabilitation under A.M.B.'s care, to identify any patients meeting criteria for nonfluent aphasia who were treated with amantadine between July 1999 and February 2001. On our unit, amantadine administered for the treatment of frontal lobe symptoms was given in a nonblinded protocol of multiple on-off sessions 2-6 days in length, to assist with determining, on an individual patient basis, whether to continue the medication at discharge. Our goal in examining this initial case series information collected on a clinical care unit was to learn whether there was evidence supporting further controlled research on amantadine in nonfluent aphasia.
Although amantadine has a longer half-life than do most clinically used stimulants, the clinical on-off regimen over multiple on-off cycles and multiple testing sessions used on the inpatient neurorehabilitation unit was based on that used for administration of stimulants for attention-deficit disorder. We suggest that it may still be appropriate to the study of amantadine for treatment of aphasia. On the basis of previous literature supporting the use of dopaminergic agents for nonfluent aphasia, 18, 19 amantadine's cognitive effects on cognition can be postulated to be transient.
SUBJECTS
We identified four records of consecutive patients admitted to the neurological rehabilitation service at the Penn State Rehabilitation Center in the year 2000 (mean 51.75 yrs of age, range 37-66 yrs; mean 10.75 yrs of education, range 8 -12 yrs) who met criteria for the diagnosis of nonfluent speech and were treated with amantadine for frontal lobe dysfunction of the amotivational type. To meet our clinical criteria for this diagnosis, subjects had to demonstrate (1) abnormal spontaneous speech and communication ability, with the conversation partner making the major portion of the effort supporting verbal communication, and (2) nonfluent spontaneous speech (fewer than 50 words per minute generated in response to an open-ended question such as "How did you come to the hospital?"). All subjects who were identified (see below) also exhibited (3) relatively spared comprehension of single words and simple commands, and (4) relatively spared repetition of single words and short phrases (e.g., no ifs, ands, or buts), consistent with a possible diagnosis of transcortical motor aphasia.
In the acute rehabilitation hospital where the study was performed, clinical assessment with an instrument permitting aphasia subtyping was not standard. Because the treating attending physician (A.M.B.) felt that syndromic subtyping of speech and language disorders was necessary to plan theoretically based treatment, resident physicians were trained to perform a bedside assessment of spontaneous speech, naming, comprehension, repetition, reading, and writing on every patient (per Albert et al. 20 and the Florida Mental Status Examination 21 ), repeated and confirmed in its essential parts by the attending physician. It should be noted that when the combination of nonfluent speech, relatively spared repetition, and comprehension were noted on assessment, we did not rigorously distinguish whether nonfluent speech was primarily a result of language abnormality or whether it was related to a primary attentional disturbance or abnormal conative function. It is possible that the subjects in this study suffered from the latter two disorders.
The subjects were all diagnosed as having a frontal lobe disorder of the primary amotivational type as part of a structured neurocognitive assessment carried out by the therapy and resident physician teams, confirmed in its essential parts by the attending physician (A.M.B.) and based on the Florida Mental Status Exam. 21 Amotivational frontal lobe dysfunction was defined as a disinclination to interact or behave that produced impairment on specific tasks and functional disability. Frontal lobe function was assessed by observing spontaneous interactive behaviors and speech, body kinesis, and activities of daily living. Our clinical criteria for the diagnosis of amotivational frontal lobe dysfunction required that subjects also have evidence of cooccurring motor response disinhibition, planning and organizational deficits, and/or deficits of abstract thinking. Although we cannot guarantee that speech therapy was completely identically administered, the same clinician treated all four patients in the study, and all patients were treated for 1 hr, 5 days/wk. This treatment situation was similar for occupational and physical therapy (although several OT/PT clinicians rotated depending on the day of treatment for these specialties). Subjects received treatment with amantadine for frontal lobe disorder as part of our inpatient rehabilitation unit's established clinical rehabilitation practice.
METHODS
Normal renal function as measured by screening blood urea nitrogen/creatinine was confirmed for all subjects before starting amantadine. We administered 100 mg of amantadine orally twice a day (6 a.m. and 6 p.m.) to all subjects in an on-off multiple-assessment protocol without blinding. On the first day, subjects received 100 mg of amantadine orally (6 a.m.), with the dosage increased to oral 100-mg doses twice a day thereafter; they were assessed between 2 and 6 days after starting amantadine. Patient 1 received four assessments, one per on-off session, with an ABAB (off-on-off-on) design. Patients 2-4 received multiple assessments per off-on session, in an ABAB protocol for patients 2 (total of six assessments) and 3 (eight assessments), and in an ABA (off-on-off) protocol for patient 4 (ten assessments), who was discharged before the last "on" session could be completed. "Off" periods commenced with 1 day during which subjects received a single, oral, 100-mg dose of amantadine (6 a.m.). Drug-washout periods lasting a mean of 4.25 days (range 3-6 days) were used.
We examined for evidence of a possible treatment effect on verbal fluency by recording the results of bedside testing with the Controlled Oral Word Association Test. 22 Subjects were asked to generate words beginning with the letters F, A, and S in 1 min, respectively, and the score was the total number of allowable words generated (no derivatives, proper names, or repeated words were permitted). A priori, we hypothesized that performance on medication would improve compared with off-medication performance. Therefore, we compared mean performance on and off medication using a one-tailed, paired-sample Student's t test.
An observed group effect may reflect improvement of similar magnitude in individual patients treated, or it may sum disparate effects in different patients. Disparate treatment effects are of obvious clinical concern, because some patients may not benefit from a treatment, or they may even experience adverse effects. We anticipated that not enough trials per patient would be available to detect individual effects with sensitivity. However, to assess for robust disparate individual effects in a preliminary fashion, we performed two-tailed, paired-sample t tests for each subject, comparing mean performance on and off medication, with the understanding that a failure to obtain significance for these comparisons might be attributable to limited power.
RESULTS
Amantadine is reported to be associated with the following side effects in more than 5% of people taking the medication: nausea, dizziness (lightheadedness), and insomnia. In 1-5% of patients, livedo reticularis, depression, irritability, hallucinations, confusion, anxiety, dry mouth, constipation, ataxia, peripheral edema, delirium, orthostatic hypotension, headache, somnolence, nervousness, dream abnormality, agitation, dry nose, diarrhea, and fatigue may occur. 23, 24 The anticholinergic-like effects of amantadine may lead to delirium or attention/memory dys-function. No side effects were reported in the patients studied during the time they took amantadine, or at any time during their hospitalization.
Off medication, participants generated a mean of 12.62 words (range, 1.5-19.5) on the Controlled Oral Word Association Test (below the first-percentile criterion for a hypothetical subject with 8 yrs of education). On medication, group mean words generated increased (mean word generation, 17.71 words; range, 3.5-28 words; t ϭ 3.38, P ϭ 0.043, two tailed). Results for each subject are presented in Table 1 .
When results were examined individually with paired-samples, two-tailed t tests, mean words generated on amantadine significantly exceeded mean words generated off amantadine for only one subject (subject 1; see Table 1 ). However, all subjects generated more mean words on than they did off medication.
DISCUSSION
This study was designed to examine preliminary data generated from clinical treatment of patients with frontal lobe syndromes with amantadine, to determine whether there is feasible rationale for further study of the drug, specifically as an agent for nonfluent aphasia. The participants in this retrospective analysis all had nonfluent speech and were diagnosed clinically as meeting criteria for diagnosis of transcortical motor aphasia (type 2). 25 Among rehabilitation professionals, transcortical motor aphasia may not be regarded as the aphasia type most requiring treatment. However, impaired fluency, and impaired language production in general, may be a more relevant target for rehabilitation than other symptoms of aphasia. 26, 27 Fluency may be impaired because of grammatical or phonetic-articulatory deficit, as occurs in classical aphasia syndromes associated with left cortical injury. However, some patients are able to generate utterances that are, from a grammatical and articulatory standpoint, well formed, but that do not initiate or elaborate verbal messages (Raymer, 2003) . 4 Although this may be an uncommon form of aphasia in people with left-hemisphere ischemic injury, in our experience, it occurs commonly in neurological rehabilitation, and the underlying causes in neurorehabilitation patients may be diverse. Patients with nonfluent speech, but relatively spared comprehension and repetition, may have a primary disorder of language, or they primarily may have impaired attention or conation. These three disorders are supported by different brain-behavior systems and are impaired by theoretically distinct mechanisms. As in the current patient group, subjects with nonfluent speech may even demonstrate primary cortical pathology in the right hemisphere. In this setting, transcortical mo- tor aphasia type 2 might be a subset of adynamic frontal lobe disorders. Although these patients are not usually classified by their medical providers as aphasic, they are almost invariably referred for, and receive, inpatient and outpatient speech therapy, acknowledging their need for improved communication ability. Appropriate treatment with medication might augment communication recovery still further.
If transcortical motor aphasia type 2 is a subset of adynamic frontal lobe disorders, it may not be surprising that our retrospective examination of verbal fluency on and off amantadine suggests that amantadine is of potential benefit. In previous reports, adynamic behavior in frontal lobe disorders seemed to improve on amantadine. 28, 29 In other patient groups not specifically identified as having transcortical motor aphasia, 30 amantadine treatment has been associated with improvement on the Controlled Oral Word Association task.
Although these findings are preliminary, we feel that they may be of pragmatic importance. Pharmacological treatments for aphasia are not yet standard in the assessment and care of aphasia. If amantadine, an inexpensive and safe drug that is easy to administer, improves verbal output even in only a subset of people with communication disorders, it may decrease the cost of care, improve functional outcomes, and positively affect patients' and families' lives. Although it is possible that only subjects with adynamic transcortical motor aphasia may benefit from amantadine treatment, this could be formally investigated in studies including subjects with other acute or chronic nonfluent aphasia syndromes.
Our study has significant limitations. Although verbal fluency improved on amantadine, fluency was still uniformly below the normal range. Although it is possible that incremental improvement in fluency improved function, we do not have any evidence that this occurred. Unfortunately, we did not specifically assess whether spontaneous word generation to an open question, or effort of communication, improved; these also would be expected to improve communicative function. We did not comeasure motor function to examine whether a general improvement in kinesis might underlie improved speech in our small group of subjects. The length of treatment needed for optimal results, additional functional and neuropsychological measures to be used to assess improvement, and timing of amantadine administration all need to be elucidated if the agent is to be recommended for clinical use; a larger, prospective patient study may help to address these issues. This retrospective chart review study included data collected in a clinical, rather than a research, setting. As a result, the treatment criteria for prescription of amantadine may not have been as rigorously defined as would be appropriate in a research setting. Also, the subjects included may have had different clinical characteristics and may have been more variable from each other than would be expected in prospective clinical research-some patients included in this report (patients 2 and 4) would be expected to improve for reasons unrelated to amantadine administration (recovery from surgery, B12 supplementation). However, spontaneous improvement does not account fully for the observed on-off medication differences. Lastly, the protocol for amantadine administration varied between subjects; this can occur in a clinical setting, but it might not be appropriate for a prospective study design. The half-life of amantadine (range, 10 -30 hrs) limits our ability to state that a therapeutic level was achieved during "on" periods, and that adequate washout occurred when the medication was discontinued for "off" assessments. However, because we observed a significant on-off difference despite this confound, the beneficial effect associated with amantadine administration might be even larger than that we observed.
Amantadine may be particularly feasible for use in rehabilitation, because clinicians are familiar with its use in the setting of brain injury, although for different indications. This medication is widely prescribed for patients with traumatic brain injury, amotivational syndromes, and minimally conscious state, and most rehabilitation professionals are experienced with its use. It is likely that clinicians would be willing to prescribe amantadine for aphasia, were they informed of possible patient benefit. At present, it is not specifically identified among reviewed agents for treatment of aphasia (e.g., Greener et al. 2 or Klein and Albert 31 ), and it is unlikely that subjects with aphasia or nonfluent speech who have a normal level of consciousness, and who do not have a history of head injury, receive it.
Amantadine's properties are not unequivocably useful to augment rehabilitation, however. It may have anticholinergic or anticholinergic-like effects on attention, thinking, and memory (e.g., Postma and Van Tilburg 32 ). We did not note impairment of memory or attention while taking amantadine among any subjects in this study. However, future controlled studies examining for beneficial effects of amantadine in aphasia may want to use verbal memory or working memory assessment as an additional outcome measure, although such instruments are not always sensitive to anticholinergic-induced cognitive changes. 33 The results of this preliminary inquiry support the feasibility of wider study of amantadine for treatment of nonfluent aphasia symptoms. We propose that investigators should plan further studies of this agent. It may be appropriate for future studies to include subjects with nonfluent speech and linguistic, attentional, and conative abnormalities, as we did in this study, including sufficient subjects numbers in each category to permit secondary subgroup analysis. We would argue that such a mixed subject group may be appropriate to study because patients with abnormal speech output may be underrepresented in the current research that is focused on measuring language improvement. Linguistic abnormalities associated with motor speech processing, such as syntactic dysfunction, are not quantified on some standard instruments such as the NIH stroke scale. 34 Thus, researchers may systematically underrepresent subjects with nonfluent speech in therapeutic studies.
We urge future rehabilitation researchers to work hard to consider all of the cognitive and functional abnormalities associated with nonfluent speech in studies of aphasia therapies. We would advocate including a range of functional outcome measures, systematic impairment assessment (measures expected to improve vs. those not expected to improve; measures expected to be sensitive to changes of the magnitude observed), and appropriately blinded assessment. Qualitative observations on and off medication, and family/caregiver assessment, may also be an important part of future research. Traditional impairment measures are more sensitive to changes in performance than the functional outcome measures that are currently used. Thus, for future studies, functional outcome measures specific to disorders causing nonfluent speech may need to be developed.
